Introduction clinical trials. As the limits of cytotoxic chemotherapy for leukaemia
The identification of several tumour-associated antiare approached, the use of other treatment modalities, gens 10 has highlighted the question as to how malignant notably immunotherapy, 1 is becoming more important, cells harbouring such antigens evade immune rejection. particularly for the eradication of minimal residual disOne possible explanation for this is the induction of ease. Several approaches have already been explored to anergy 11 due to the absence of the essential second signal induce/enhance antileukaemic immunity with only limfor T cell activation. 12 Following cell-cell contact through ited success; these include immunisation with autologinteraction of cell adhesion molecules, 13 two signals are ous 2 or allogeneic leukaemic cells, 3 adoptive immunorequired: (1) recognition of antigenic peptide by the T cell therapy 4 and systemic administration of recombinant receptor (TCR) in the context of the appropriate MHC; cytokines (eg IL-2). 5 Gene transfer of immunoregulatory and (2) a second costimulatory signal. Costimulation can genes (eg IL-2, 6 IL-4, 7 GM-CSF, 8 B7. 1 9 ) into cancer cell be provided by several molecules, although the most lines has been shown in several animal models to reduce potent costimulation comes from interaction of B7.1 tumorigenicity, and more importantly, in some models (CD80) and B7.2 (CD86) with their cognate receptor, gene-modified cells have been shown to be able to cure CD28 (reviewed in Ref. 14) . 14 In the absence of costimuanimals with established, unmodified tumours.
lation, instead of activation, TCR engagement induces antigen-specific anergy, 11 in which T cells are unable to be activated through further TCR signalling, even when costimulation is provided. Both B7.1 and B7.2 are type role. 17 Despite being ligands for the same receptors, difhave looked, therefore, at the effect of haemopoietic growth factors (stem cell factor, IL-3, GM-CSF) on transferences in function between B7.1 and B7.2 have been described. 18 The importance of B7-CD28 interaction in duction efficiency and examined whether any effect is related to cell cycling. As CD28-B7 interaction plays an immune responses is highlighted by blocking studies showing prolonged survival of xenografts 16 and inhiessential role in alloreactions, we have used a mixed leukaemic cell/allogeneic T cell reaction (MLLR) to demonbition of graft-versus-host disease. [19] [20] [21] Thus, B7.1/B7.2 and CD28/CTLA4 interaction is likely to play a key role strate immune costimulatory activity of transduced cells to confirm that B7.1 gene modification can alter the in determining the nature of the immune response to a given antigen.
immune response. As most malignant cells do not express costimulatory molecules, tolerance to tumour-associated antigens could
Results
arise following the development of anergy. The first evidence for this concept was reported by Chen et al, 9 and B7.1 expression by primary AML blasts supported by others in subsequent studies using models B7.1 expression was analysed by flow cytometry in 32 of both solid tumours [22] [23] [24] [25] and leukaemia. 26, 27 These have consecutive cases of AML referred to this Hospital for demonstrated that B7.1 expression by malignant cells can diagnostic immunophenotyping (M1 three, M2 nine, M3 induce immune-mediated rejection of the gene-modified five, M4 10, M5 four, myeloid blast crisis of chronic grancells, and also protect from a subsequent challenge with ulocytic leukaemia one). No significant B7.1 expression unmodified cells (reviewed in Ref. 28) . 28 The role of B7.2 was demonstrated in any case, including the 10 cases has also been examined, albeit less intensively, and a used in the subsequent study. These cases all expressed similar effect found. 29, 30 An important finding seen in MHC class I (78-99% of cells; median 93%) and MHC both murine myeloid leukaemia models reported, 26, 27 is class II (13-97% of cells; median 50%). that a therapeutic effect can be produced when B7.1 genemodified cells are administered to animals with estabRelationship between in vitro growth patterns and lished leukaemia, however, B7.1 modified cells must be transduction efficiency given early to be curative. This is probably due to either Efficiency of gene transfer, judged by the initial frethe vigorous leukaemic growth, a rapid onset of anergy, quency of B7.1 expression of the total suspension cells or the consequence of generalised immunosuppression immediately after transduction, varied from 0.3 to 8.2 % observed in tumour-bearing subjects. 31 A synergistic (median 1.5) in the absence of additional HGFs ( Figure  effect with coexpression of B7.1 with a T cell growth fac-1). HGFs increased transduction, as is seen in normal tor (eg IL-2, 6 IL-7 32 ) has been observed, which may be haemopoietic progenitors. 48 Stem cell factor (SCF) alone particularly important in the therapeutic setting.
increased transduction (median 2.7%), which was further Haematological malignancies would appear to be increased by the addition of granulocyte-macrophage particularly suitable to gene modification with B7.1, as colony-stimulating factor (GM-CSF) and IL-3 (median they possess two of the three requirements for T cell acti-3.9%). The greatest response to HGFs was seen in cases vation: expression of MHC and appropriate cell adhesion with the highest initial transduction, and no response molecules, while lacking B7.1. Myeloid leukaemia cells observed in others. Cell cycle analysis (S, G2/M or total generally express MHC class I and, to a lesser degree, fraction in cycle) failed to demonstrate a correlation with class II, as well as cell adhesion molecules (eg ICAMs, transduction efficiency (Figure 2a and b) . The increment LFA-1, LFA-3) [33] [34] [35] required for interaction with T cells. 13 could, therefore, only be partly explained by changes in Leukaemia-associated antigens have yet to be identified proliferation, which again was more apparent in those for myeloid leukaemias, however, acquired genetic with an initial high fraction in cycle ( Figure 3 ). Assays of abnormalities identified in haematological malignancies can be recognised by specific T cells (chimeric gene products, 36 ,37 mutated oncogenes 38 and tumour suppressor genes 39 ). These may have the potential to act as leukaemia-specific antigens, although the experience with melanoma suggests that re-expressed developmental genes or tissue-specific genes are a greater source of tumour-associated antigens. 10 The granulocytic-specific proteins, myeloperoxidase and proteinase 3, found in AML 40 can both act as autoantigens, [41] [42] [43] and would be a further potential target, comparable to tyrosinase in melanoma. 44 This concept is currently under investigation. 45 The requisite properties would therefore appear to be present in primary AML cells to warrant examining the use of B7.1 gene-modified primary leukaemic cells to induce antileukaemic immunity. In this study, we have examined retrovirus-mediated vectors will have a low efficiency of gene transfer. We ance gene is driven by an internal promoter).
Primary AML cells were transduced by 48 h co-culture on irradiated producer cells. Cell cycle analysis was performed using dual BrDU/anti-

Selection of transduced cells
BrDU and propidium iodide staining. Transduction efficiency was judged
The limited duration of culture and slow action of hygro-
by the percentage of cells expressing human B7.1 by anti-B7.1 binding. (a) Fraction of cells in G2/M phase; (b) total fraction in cycle (ie S + G2/M).
mycin, restricted the expansion of B7.1-positive cells. To examine if targeting the population of cells with the greatest proliferative capacity (ie CD34 positive) increased transduction efficiency, we looked at infecting CD34-enriched AML cell populations. CD34 enrichment before transduction did not significantly increase transduction efficiency, however, the more sustained growth of these cells enabled the generation of a more highly selected population ( Figure 6 ). Triple labelling with CD34, CD38 and B7.1 ( Enhancement of costimulation by B7.1 transduced AML blasts hygromycin-resistant AML colonies (CFU-AL) indicated higher gene transfer into clonogenic cells than the total
The functional activity of the B7.1gene product was tested in a mixed leukaemia cell/T cell reaction ( Figure  population (Figure 4 ), but no increment was observed with the addition of HGFs. 7). Unmodified AML cells, which had been similarly treated to the transduced cells, were unable to stimulate The lack of correlation with cell cycle reflects the multiple factors (ie virus-binding, integration events and a significant reaction. Equally, mock-infected cells could blasts; 51 and in vivo gene transfer by direct intra-tumoral injection. 52 In this study, we have shown that by using a metric analysis showed the activated (CD25 or CD69 + ) T cells in the MLLR to be either CD4 + or CD8 + (data not replication incompetent retroviral vector it is possible to introduce an immune costimulator B7.1 (CD80) into shown). Figure 6 .
judged by B7.1 expression. However, the observation of hygromycin-resistant CFU-AL comparable to other cases, and the presence of viral sequences detected by PCR suggested the cells were infected, but there was either a failprimary AML blasts, albeit with low efficiency, and by immunoselection, enrich the transduced cells for ure of viral promoter (LTR) activity or post-transcriptional inhibition. subsequent administration for autologous cellular immunisation.
In 32 cases of primary AML we have been unable to demonstrate expression of B7.1, even in monocytic leuMurine leukaemia viruses (the origin of most retroviral vectors) are dependent on cell division for integration kaemias, in which this would be most likely. However, it should be noted that in two cases of acute monocytic into the host genome. 46 Primary AML cells generally have a low proliferative rate, usually less than their norleukaemia, which were initially negative, B7.1 expression could be induced by in vitro culture, and were consemal counterparts. 47 In this study we have been unable to demonstrate a high correlation between the fraction of quently excluded from this study. A similar finding has been observed with ␥-interferon, again in some cases of cells in cycle and transduction efficiency. Retroviral vectors (amphotropic) enter the cell via binding to the acute monocytic leukaemia. 56 In the other cases, neither the culture conditions used, nor infection with the empty amphotropic receptor, which is expressed on most mammalian cells and is probably a phosphate transport chanvector or ecotropic virus (tropism restricted to murine cells) induced expression in the cases included in the nel. 53, 54 Variable expression of this receptor may therefore partly explain the unpredicted transduction of some analysis. The limited in vitro growth capacity of primary AML cases for the level of mitotic activity. Addition of haemopoietic growth factors increases retrovirus-mediated gene cells restricts the use of drug selection to enrich the trans-duced population. CD34 enrichment before transduction transduction efficiency with retroviral vectors, isolate cells expressing both genes by immunoselection for the selects the population with the greatest proliferative capacity and enriches for the putative leukaemia-initiatsurface expressed gene, providing the opportunity to examine in clinical studies the ability of gene-modified ing cell (CD34 + CD38 − ). 49 This procedure produces a population with more sustained growth thus enabling (eg B7.1 and IL-2) autologous cells to induce antileukaemic immunity. selection of drug-resistant cells. However, this strategy is not universally applicable and is restricted to only those cases with initially high CD34 expression. Immunoselec-
Materials and methods
tion has been used in other gene therapy strategies to select transduced cells by using a surface expressed transgene rather than a co-expressed drug resistance gene as Cells a selectable marker, eg truncated nerve growth factor Primary AML cells were collected from either the periphreceptor, 57 CD24. 58 We have used a similar strategy here eral blood (including leukapheresis) or bone marrow of to isolate B7.1 gene-modified leukaemic cells. patients referred to this hospital for treatment or diagnosMixed lymphocyte reactions (MLR) require the prestic purposes. Mononuclear cells (Ͼ95% leukaemic cells) ence of antigen-presenting cells, probably by providing were obtained by density-gradient separation (Ficollessential immune costimulation through B7-CD28 interHypaque; Pharmacia Biotech, Milton Keynes, UK). Cells actions. This is illustrated by the inability of AML cells were frozen in aliquots in RPMI 1640, 40% serum and to induce an MLR despite the expression of MHC class 10% DMSO. CD34-positive cells were selected using a I and class II. 59 Alloreactive T cells are able to recognise CEPRATE LC34 Biotin Laboratory Cell Separation Sysforeign MHC on the surface of allogeneic cells (direct tem (CellPro, Bothall, WA, USA) as per the manufacallorecognition), as well as recognising peptides derived turer's instructions. PA317 (kindly provided by Dr from alloantigens (minor or major histocompatibility) in Arthur Bank, Columbia University, New York, USA) and the context of self-MHC (indirect allorecognition). 60 As GP+E86 were grown in DMEM with 10% FCS. we used allogeneic T cells depleted of antigen-presenting cells, the observed T cell activation must be primarily via
Vectors and producer cells direct allorecognition of HLA molecules on AML cells, Human B7.1 cDNA was generated by RT-PCR from total with costimulation being provided by the presence of human RNA extracted from human peripheral blood B7.1 on gene-modified cells. Whether B7.1 expression by mononuclear cells. This has been sequenced and its malignant cells alone is capable of activating naïve T cells identity confirmed by comparison with the published is unclear. One study suggests that dendritic cells effect sequence (accession number M27533). B7.1 cDNA was primary responses, but that B7.1-transduced cells can cloned into a disabled retroviral vector, M 3 P-SVHYstimulate secondary responses. 61 However, in alloreac-GRO, 68 and this was used to transfect the ecotropic packtions, both memory and naïve T cells are involved, 62 indiaging cell line GP+E86. Supernatant from this transfectant cating that this is not a pure primary response. In our was used to infect the amphotropic packaging cell line MLLR, B7.1-transduced AML cells, therefore, may be PA317 and producer cell clones were isolated in the presexpected to be capable of directly stimulating alloreactive ence of hygromycin (Calbiochem, Nottingham, UK). Sur-T cells. Even if some residual dendritic cells remain in face expression of hB7.1 clones was determined by the effector populations following depletion, indirect CTLA4.Ig binding (kindly provided by Peter Linsley, Briallorecognition would be the same for unmodified and stol Myers Squibb, Seattle, WA, USA). One clone with B7.1-transduced AML cells, and cannot explain the differhigh hB7.1 expression and a viral titre of 10 6 c.f.u./ml ence seen. It is plausible, therefore, that in the MLLR, was used for infections. M 3 P-SVHYGRO producer cells alloreactive T cells directly recognise non-self HLA on were similarly generated for use in mock infections. AML cells, with costimulation being provided by B7.1 transgene expression leading to T cell proliferation, which is inhibited by CTLA4.Ig. The other CD28/CTLA4
Culture conditions and transduction protocol Leukaemic cells were grown in Iscove's modified Dulbecligand, B7.2 (CD86), was weakly expressed (Ͻ10% positive) in only three of the cases studied. It is, therefore, co's medium containing 10% fetal calf serum, 10% horse serum-donor herd, penicillin-streptomycin and l-glutanot possible to determine which is the more potent costimulator in alloreactions using this model, although mine (all from Sigma, Poole, UK) (complete medium) at 5 × 10 6 to 1 × 10 7 /ml. Sera were heat-inactivated at 56°C the absence of an alloreaction to AML cells seen in this and other studies suggests B7.1 is a more effective for 30 min. Growth factors were kept at concentrations of 20 ng/ml recombinant human stem cell factor (R&D costimulator of alloreactions.
In this study, we have shown that retrovirus-mediated Systems, Oxon, UK), 10 ng/ml recombinant human GM-CSF (Schering-Plough, Bury St Edmunds, UK) and 10 gene transfer combined with immunoselection enables rapid production of autologous gene-modified AML ng/ml recombinant human IL-3 (Sandoz Pharmaceuticals, Camberley, UK). Cells were cultured at 37°C and cells, and have demonstrated enhanced immune costimulatory activity of these cells. However, a more effective 5% CO 2 . In experiments using cryopreserved leukaemic cells, the cells were grown for 24 h before transduction. immune response may be generated with gene-modified malignant cells co-expressing an immune costimulator Transduction was performed by co-culturing leukaemic cells on ␥-irradiated (100 Gy) packaging cells for 48 h and a T cell growth factor (eg IL-2, 63 IL-7 32 ), possibly by reversing anergy, 64 amplifying T cell responses, or preunder the above conditions. Packaging cells were grown to confluence, and washed twice in complete medium venting T cell signalling defects. 65, 66 It is now possible to obtain expression of multiple genes (eg B7.1 and IL-2) prior to irradiation. For selection of resistant cells, hygromycin was added at a concentration of 300 g/ml. using a single polycistronic vector, 67 and, despite the low
Flow cytometry
Bergisch Gladbach, Germany) according to the manufacturer's instructions. For flow cytometric analysis of gene expression, the following antibodies were used (all from Becton Dickinson, Mixed leukaemic cell/T lymphocyte reactions (MLLR) Oxford, UK unless specified): anti-B7.1/BB1 (clone The functional activity of B7.1-transduced leukaemic cells L307.4); anti-CD4-PE (clone Q4120; Sigma); anti-CD8-PE was tested in an allogeneic model. Purified allogeneic T (clone UCHT4; Sigma); anti-CD25-FITC (clone 2A3); anticells were used as responders to primary AML cells from CD34-FITC (clone 8G12); anti-CD38-PE (clone HB-7); seven patients (those with the highest transduction anti-CD69-FITC (clone L78); anti-HLA class I (clone efficiency) who were transduced and selected as above. W6/32-HL; Cymbus Bioscience, Southampton, UK); and Unmodified cells were treated similarly with respect to anti-HLA-DR (clone L234). FITC-conjugated rabbit antitime in culture, replating and exposure to growth factors. mouse Ig Fab 2 was used as the secondary antibody for Allogeneic T cells from two different random donors single colour analysis and goat anti-mouse Ig were isolated by density-gradient separation followed by biotin/streptavidin-red (Sigma) for triple labelling studeither positive selection of CD4 and CD8 cells with ies. Flow cytometric analyses were performed with a immunomagnetic beads (Dynal, Oslo, Norway), or by FACScan or FACStar plus (Becton Dickinson).
negative selection, ie depletion of adherent cells (3 h at 37°C) followed by passage through an immunoaffinity Cell cycle analysis column to remove residual macrophages and B cells Leukaemic cells were grown in complete medium with (R&D Systems, Abingdon, UK). To test the role of B7 in or without HGFs for 24 h followed by the addition of 10 the reaction, AML blasts (30-60% B7.1 + ) were incubated g/ml bromodeoxyuridine (Sigma) for 2 h. Cells were either with or without 10 g/ml CTLA4.Ig for 30 min then fixed and labelled with anti-BrDU-FITC (Becton before co-culture with T cells. Irradiated (40 Gy) AML Dickinson) according to the manufacturer's instructions.
blasts (unmodified, B7.1 transduced or mock-infected) Cell cycle analysis was performed on 100 l of cell susand allogeneic T cells were plated 1:1 in round-bottomed pension, at a concentration of 4 × 10 6 cells/ml, mixed 96-well plates at 10 5 per well in triplicate in RPMI supwith 400 l of 50 g/ml propidium iodide (Sigma) plemented with heat-inactivated human AB serum immediately before analysis. Apoptotic cells were (Sigma) for 5 days at 37°C in 5% CO 2 . After 5 days, 3 Hexcluded from the calculations, due to variable recovery thymidine (Amersham International, Little Chalfont, UK) from liquid nitrogen.
was added at 1 Ci per well for 20 h. The cells were then harvested and counted. To control for the possibility of CFU-AL assay nonspecific T cell stimulation by a small number of conFollowing transduction, AML cells were plated in 3.5 cm taminating virus producer cells, M 3 P.HB7 or M 3 P-SVHYsix-well tissue culture plates at 10 5 /ml in 0.9% methyl GRO producer cells were irradiated with 100 Gy then cellulose (Stem Cell Technologies, Vancouver, Canada), kept in culture for 48 h and irradiated again with 30 Gy IMDM, 20% FCS and recombinant growth factors (SCF before adding to the co-cultures (ie similarly treated to 100 ng/ml, IL-3 50 ng/ml, GM-CSF 50 ng) with or withthose potentially contaminating the blasts). These were out 300 g/ml hygromycin. Assays of unmodified cells co-cultured 1:1, 1:100 and 1:10,000 with T cells. were set up in parallel. The cultures were incubated at 37°C in 5% CO 2 for 10 days at which time the number of colonies (defined as more than 25 cells) were counted.
